Report from Annual General Meeting of Vitrolife AB (publ)
Vitrolife held its Annual General Meeting, approving several key decisions for 2025. Shareholders approved a dividend of SEK 1.10 per share for 2024, with May 2, 2025, set as the record date.
The board saw the re-election of five members, with J贸n Sigurdsson appointed as Chairman. Total board remuneration increased to SEK 3.67 million, up from SEK 3.3 million. Deloitte AB was re-elected as auditor.
Key authorizations granted include:
- Permission to issue up to 13,544,719 shares (10% of share capital)
- Authority to acquire company shares (max 10% of total shares)
- Implementation of a share-based incentive program with 480,000 warrants
The meeting also approved new guidelines for executive management compensation.
Vitrolife ha tenuto l'Assemblea Generale Annuale, approvando diverse decisioni chiave per il 2025. Gli azionisti hanno approvato un dividendo di 1,10 SEK per azione per il 2024, con il 2 maggio 2025 come data di riferimento.
Il consiglio ha visto la rielezione di cinque membri, con J贸n Sigurdsson nominato Presidente. La remunerazione totale del consiglio 猫 aumentata a 3,67 milioni di SEK, rispetto ai 3,3 milioni precedenti. Deloitte AB 猫 stata rieletta come revisore dei conti.
Le principali autorizzazioni concesse includono:
- Permesso di emettere fino a 13.544.719 azioni (10% del capitale sociale)
- Autorizzazione ad acquisire azioni della societ脿 (max 10% del totale azioni)
- Implementazione di un programma incentivante basato su azioni con 480.000 warrant
L'assemblea ha inoltre approvato nuove linee guida per la remunerazione del management esecutivo.
Vitrolife celebr贸 su Junta General Anual, aprobando varias decisiones clave para 2025. Los accionistas aprobaron un dividendo de 1,10 SEK por acci贸n para 2024, con fecha de registro el 2 de mayo de 2025.
Se reelegieron cinco miembros del consejo, y J贸n Sigurdsson fue nombrado Presidente. La remuneraci贸n total del consejo aument贸 a 3,67 millones de SEK, desde 3,3 millones. Deloitte AB fue reelegida como auditor.
Las autorizaciones clave otorgadas incluyen:
- Permiso para emitir hasta 13.544.719 acciones (10% del capital social)
- Facultad para adquirir acciones de la empresa (m谩ximo 10% del total de acciones)
- Implementaci贸n de un programa de incentivos basado en acciones con 480.000 warrants
La junta tambi茅n aprob贸 nuevas directrices para la compensaci贸n de la alta direcci贸n.
Vitrolife電� 2025雲勳潉 鞙勴暅 鞐煬 欤检殧 瓴办爼鞚� 鞀轨澑頃橂┌ 鞐半 欤检＜齑濏殞毳� 臧滌禍頄堨姷雼堧嫟. 欤检＜霌れ潃 2024雲� 氚半嫻旮堨溂搿� 欤茧嫻 SEK 1.10鞚� 鞀轨澑頄堨溂氅�, 旮办鞚检潃 2025雲� 5鞗� 2鞚茧 鞝曧暣臁岇姷雼堧嫟.
鞚挫偓須岆姅 雼れ劘 氇呾潣 鞚挫偓 鞛劆鞛勱臣 頃粯 J贸n Sigurdsson鞚� 鞚橃灔鞙茧 靹犾瀯頄堨姷雼堧嫟. 鞚挫偓須� 齑� 氤挫垬電� SEK 3.3氚彪鞐愳劀 SEK 3.67氚彪鞙茧 歃濌皜頄堨姷雼堧嫟. Deloitte AB臧� 臧愳偓搿� 鞛劆鞛勲悩鞐堨姷雼堧嫟.
欤检殧 鞀轨澑 甓岉暅鞚� 雼れ潓瓿� 臧欖姷雼堧嫟:
- 斓滊寑 13,544,719欤�(鞛愲掣旮堨潣 10%)旯岇 鞁犾＜ 氚滍枆 項堦皜
- 須岇偓 欤检嫕 斓滊寑 10%旯岇 旆摑 甓岉暅
- 480,000 鞗岆煱韸鸽ゼ 韽暔頃� 欤检嫕 旮半皹 鞚胳劶韹半笇 頂勲攴鸽灗 鞁滍枆
齑濏殞電� 霕愴暅 瓴届榿歆� 氤挫儊鞐� 雽�頃� 靸堧鞖� 歆�旃潉 鞀轨澑頄堨姷雼堧嫟.
Vitrolife a tenu son Assembl茅e G茅n茅rale Annuelle, approuvant plusieurs d茅cisions cl茅s pour 2025. Les actionnaires ont approuv茅 un dividende de 1,10 SEK par action pour 2024, la date de r茅f茅rence 茅tant fix茅e au 2 mai 2025.
Cinq membres du conseil ont 茅t茅 r茅茅lus, avec J贸n Sigurdsson nomm茅 Pr茅sident. La r茅mun茅ration totale du conseil a augment茅 脿 3,67 millions de SEK, contre 3,3 millions auparavant. Deloitte AB a 茅t茅 r茅茅lu en tant qu鈥檃uditeur.
Les principales autorisations accord茅es comprennent :
- Permission d鈥櫭﹎ettre jusqu鈥櫭� 13 544 719 actions (10 % du capital social)
- Autorisation d鈥檃cqu茅rir des actions de la soci茅t茅 (maximum 10 % du total des actions)
- Mise en place d鈥檜n programme d鈥檌ncitation bas茅 sur des actions avec 480 000 bons de souscription
L鈥檃ssembl茅e a 茅galement approuv茅 de nouvelles directives pour la r茅mun茅ration de la direction ex茅cutive.
Vitrolife hielt seine Jahreshauptversammlung ab und genehmigte mehrere wichtige Entscheidungen f眉r 2025. Die Aktion盲re stimmten einer Dividende von 1,10 SEK pro Aktie f眉r 2024 zu, mit dem 2. Mai 2025 als Stichtag.
Der Vorstand wurde mit f眉nf Mitgliedern wiedergew盲hlt, und J贸n Sigurdsson wurde zum Vorsitzenden ernannt. Die Gesamtverg眉tung des Vorstands stieg auf 3,67 Millionen SEK von zuvor 3,3 Millionen. Deloitte AB wurde als Abschlusspr眉fer wiedergew盲hlt.
Wichtige erteilte Genehmigungen umfassen:
- Erlaubnis zur Ausgabe von bis zu 13.544.719 Aktien (10 % des Grundkapitals)
- Erm盲chtigung zum Erwerb von Gesellschaftsanteilen (max. 10 % der Gesamtaktien)
- Einf眉hrung eines aktienbasierten Anreizprogramms mit 480.000 Optionsscheinen
Die Versammlung genehmigte au脽erdem neue Richtlinien f眉r die Verg眉tung der Gesch盲ftsleitung.
- Dividend payment of SEK 1.10 per share approved for 2024
- Board authorization to issue up to 13.5M new shares (10% of capital) for potential growth opportunities
- Implementation of share-based incentive program to align management interests with shareholders
- Board remuneration increased by 11.2% to SEK 3.67M from SEK 3.3M
- Potential share dilution risk up to 10% from new share issuance authorization
- Additional dilution possible from 480,000 warrants issued for incentive program
- Resolution in accordance with the Board's proposed dividend of听SEK 1.10 per share for the financial year 2024. 2 May, 2025 was adopted as the record day.
- Re-election of Board members Henrik Blomquist, Lars Holmqvist, Pia Marions, J贸n Sigurdsson and Karen Lykke S酶rensen, in accordance with the election committee's proposal. J贸n Sigurdsson was elected Chairman of the Board.
- Remuneration to the Board members is proposed to be in total
SEK 3 670 000 (3 300 000) of whichSEK 1 350 000 (1 200 000) to the Chairman of the Board,SEK 450 000 (400 000) to each of the other members of the Board,SEK 160 000 (150 000) to the Chairman of the Audit Committee andSEK 80 000 (75 000) to each of the other members of the Audit Committee. - Re-election of Deloitte AB as auditor with unchanged remuneration principles.
- Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to resolve to issue a maximum of 13,544,719 shares in total, corresponding to just below 10 percent of the company's share capital.
- Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to resolve on acquisition of the company's own shares. The Company can at no time hold more than 10 percent of the total shares in the Company.
- The proposed guidelines for remuneration and other conditions of employment for the executive management team were approved.
- Implementation of a share-based incentive program including issue of a maximum number of 480,000 warrants to a wholly owned subsidiary of Vitrolife AB and approval that the subsidiary may transfer shares and/or warrants and of hedging activities.
VITROLIFE AB (publ)
The Board
The information was submitted for publication, through the agency of the contact persons set out above, at听30-04-2025 09:08 CET.
Contact:听
Helena Wennerstr枚m, acting CFO, phone: +4670 822 80 86
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision
The following files are available for download:
| Report from Annual General Meeting of Vitrolife AB (publ) |
听
View original content:
SOURCE Vitrolife AB (publ)
FAQ
What dividend did Vitrolife (VTRLY) announce for 2024?
How many shares can Vitrolife (VTRLY) issue under the new authorization in 2025?
What is the new Board compensation structure for Vitrolife (VTRLY) in 2025?
How many warrants did Vitrolife (VTRLY) approve in their 2025 incentive program?
What share buyback authorization was approved at Vitrolife's 2025 AGM?
